Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334477 | 1.00 | HDAC2 (0.48) | HDAC2MGLLCA1HDAC1HDAC6 | |
| SCHEMBL6834934 | 0.86 | MAOB (0.50) | HDAC2CA1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL27745 | 0.86 | MAOB (0.50) | HDAC2CA1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL27746 | 0.86 | MAOB (0.50) | HDAC2CA1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL8499276 | 0.82 | BCL2L1 (0.43) | HDAC2CA1HDAC1HDAC6MAOB | |
| SCHEMBL8499272 | 0.82 | BCL2L1 (0.43) | HDAC2CA1HDAC1HDAC6MAOB | |
| SCHEMBL1287794 | 0.78 | KDM4E (0.52) | HDAC2MGLLCA1HDAC1HDAC6 | |
| SCHEMBL11265587 | 0.78 | KDM4E (0.52) | HDAC2MGLLCA1HDAC1HDAC6 | |
| SCHEMBL9171323 | 0.78 | CA1 (0.62) | HDAC2MGLLCA1HDAC1HDAC6 | |
| SCHEMBL76158 | 0.78 | CA1 (0.62) | HDAC2MGLLCA1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691805-B2 | Antimicrobial compounds | NEOBIOTICS AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| EP-2019819-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | Neobiotics AB (SE) | 2009-02-04 | — | — | EP | disclosed |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | NEOBIOTICS AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008124756-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2007129952-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | NEOBIOTICS AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | NEOBIOTICS AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | ARG1, ARGLU1, VIP | HDAC2 1767/4885MGLL 1783/4885CA1 789/4885 |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | VIP, ARG1, PEPD | HDAC2 1891/4885MGLL 2760/4885CA1 898/4885 |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | HDAC2 4176/4885MGLL 3106/4885CA1 4648/4885 |
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | BDKRB1, BDKRB2, HPGDS | HDAC2 1756/4885MGLL 3645/4885CA1 513/4885 |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | ARG1, C1R, ARG2 | HDAC2 469/4885MGLL 3380/4885CA1 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.